LP
SPRO icon

LMR Partners’s Spero Therapeutics SPRO Stock Holding History

LMR Partners’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,508
Closed -$23K – 1256
2022
Q3 		$23K Hold
11,508
– – ﹤0.01% 1154
2022
Q2 		$9K Buy
+11,508
New +$33.5K ﹤0.01% 1257

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LMR Partners's SPRO Position: Q4 2022 in Review

LMR Partners sold out of Spero Therapeutics (SPRO) in Q4 2022, closing a stake of 11,508 shares — an estimated $23K sold.

LMR Partners first reported a position in SPRO in Q2 2022 and held it in 2 quarters. The position peaked at $23K in Q3 2022. 60 funds tracked by Wall St. Rank hold SPRO as of Q4 2022.

  • LMR Partners reported no remaining Spero Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 11,508 Spero Therapeutics shares in Q4 2022, an estimated $23K.
  • LMR Partners first reported a position in Spero Therapeutics in Q2 2022 and held it in 2 quarters.
  • LMR Partners's Spero Therapeutics position peaked at $23K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.